Production (Stage)
Ventyx Biosciences, Inc.
VTYX
$1.69
-$0.13-7.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.20M | 7.60M | 7.92M | 7.91M | 8.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.10M | 32.42M | 38.55M | 35.71M | 41.77M |
| Operating Income | -30.10M | -32.42M | -38.55M | -35.71M | -41.77M |
| Income Before Tax | -27.44M | -29.35M | -35.25M | -31.95M | -38.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.44M | -29.35M | -35.25M | -31.95M | -38.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.44M | -29.35M | -35.25M | -31.95M | -38.57M |
| EBIT | -30.10M | -32.42M | -38.55M | -35.71M | -41.77M |
| EBITDA | -30.00M | -32.35M | -38.49M | -35.65M | -41.70M |
| EPS Basic | -0.39 | -0.41 | -0.50 | -0.45 | -0.62 |
| Normalized Basic EPS | -0.24 | -0.26 | -0.31 | -0.28 | -0.39 |
| EPS Diluted | -0.39 | -0.41 | -0.50 | -0.45 | -0.62 |
| Normalized Diluted EPS | -0.24 | -0.26 | -0.31 | -0.28 | -0.39 |
| Average Basic Shares Outstanding | 71.13M | 70.81M | 70.67M | 70.55M | 61.83M |
| Average Diluted Shares Outstanding | 71.13M | 70.81M | 70.67M | 70.55M | 61.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |